Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fortesta for Pain Sensitivity in Men with Hypogonadism and Chronic Pain
NCT01689896Phase 4Withdrawn
- Sponsor
- Johns Hopkins University
- Start
- Aug 2012
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of AndroForte in Hypogonadism, sponsored by Johns Hopkins University. Primary endpoints: Cold Pressor Test Pain Tolerance at 18 weeks and Pressure Pain Threshold at 18 weeks. Planned start Aug 2012; status: withdrawn.
02
Drugs
AndroForte
03
Conditions
Hypogonadism
Beyond the preview
Go deeper on NCT01689896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01689896.